CEO Of Atossa Genetics (NasdaqCM: ATOS) Stated: “We have reached an important milestone!”
Steve Quay, President, and CEO of Atossa Genetics (NasdaqCM: ATOS) a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions stated:
“We have reached an important milestone by completing enrollment in both the topical and oral arms of our Phase 1 Endoxifen study. We look forward to announcing preliminary top-line results from the topical arm of our endoxifen study later this quarter.”
Yesterday Atossa Genetics announced Second Quarter ended June 30, 2017 financial results and provided an update on recent company developments. Their recent corporate developments were reported as follows:
1. Completed capital raise of approximately $4.4 million gross proceeds.
2. Eliminated warrants to purchase approximately 3 million shares of common stock through cashless warrant exercises on June 30 and subsequent to that eliminated warrants to purchase approximately an additional 1.6 million shares of common stock through cash exercises.
3. Received multiple positive interim safety assessments from the safety committee on our proprietary Endoxifen Phase 1 dose escalation study.
4. Completed the transfer of the Fulvestrant Microcatheter Phase 2 study to Montefiore Medical Center.
To learn more about Atossa Genetics (NasdaqCM: ATOS) please bookmark ATOS’s Company dedicated page at the Vista Partners Coverages Pages and quickly register as a Member at The Vista Partners site to receive free updates directly to your email.